Biotechnology company Nanoscope Therapeutics recently announced the formation of Vision Advisory Committee (VAC). 1 VAC is “a group of renowned experts in retina treatment and commercialization,” a ...

Christine Kay, MD, presented interim 1-year data from a phase 1/2 study of an investigational gene therapy (OPGx-LCA5; Opus Genetics) for LCA5-related Leber congenital amaurosis at the Clinical Trials ...

Breye Therapeutics announced the successful completion of its phase 1b clinical trial of an oral therapy, danegaptide, for early treatment of non-proliferative diabetic retinopathy (NPDR) and ...

Clinical-stage biotechnology company PYC Therapeutics recently held a type B meeting with the US Food and Drug Administration (FDA) to discuss requirements for a new drug application (NDA) for the ...

Robert Collier said, “success is the sum of small efforts, repeated day in and day out.” So, as we approach the busiest retina meeting season, remember each small effort and give these pearls a try.

Researchers with the National Institutes of Health (NIH) has identified in a recent study which brain circuits are essential for visual acuity and how they may be affected by retinal cell damage. The ...

The Retina World Congress 2025, led by President Barry Kuppermann, represents a pivotal moment in ophthalmological innovation, bringing together international retina specialists to discuss ...

In a comprehensive study of geographic atrophy (GA) treatment, Deepak Sambhara, MD, from the Eye Clinic of Wisconsin analyzed long-term patient compliance with two recently FDA-approved complement ...

Priya Vakharia, MD, a retina specialist at Retina Vitreous Associates of Florida in Tampa Bay, presented findings from the ARCHER trial investigating geographic atrophy (GA) treatment for dry ...

Biotechnology company Lineage Cell Therapeutics recently announced it will be presenting data from its phase 1/2a clinical study (NCT02286089) at the upcoming Clinical Trials at the Summit (CTS) 2025 ...

Kriya Therapeutics recently announced preclinical data on its gene therapy candidate KRIYA-825, a one-time gene therapy delivered by suprachoroidal injection, for the treatment of geographic atrophy ...

Ashvattha Therapeutics recently announced positive interim phase 2 results for migaldendranib (MGB). 1 MGB is described as a novel subcutaneously administered nanomedicine for the treatment of retinal ...